Lifesplice Pharma LLC is an early stage biotech company developing long lasting RNA based drugs called splice modulating oligomers (SMOs) to treat several neurological disorders. Lifesplice Pharma was co-founded by Gordon J. Lutz, and Melanie Tallent, developed Splice Modulating Oligomers (SMOs) that directly modulate dysregulated pre-mRNA splicing and alternative splicing which are both frequently linked to severe neurological disorders. The program consists 2 preclinical stage small molecules against ALS and Epilepsy.
LifeSplice Pharma LLC
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/lifesplice-pharma” connections=”true” suffix=””]
LifeSplice was awarded more than $3.7 Mn NIH Phase 2 and 1 SBIR grant for IND-enabling GLP Saftey + CMC studies of our lead drug LSP-GR1 for treating ALS.